169 related articles for article (PubMed ID: 1692349)
1. Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization.
Hansen JE; Clausen H; Nielsen C; Teglbjaerg LS; Hansen LL; Nielsen CM; Dabelsteen E; Mathiesen L; Hakomori SI; Nielsen JO
J Virol; 1990 Jun; 64(6):2833-40. PubMed ID: 1692349
[TBL] [Abstract][Full Text] [Related]
2. Murine monoclonal antibodies biologically active against the amino region of HIV-1 gp120: isolation and characterization.
Dickey C; Ziegner U; Agadjanyan MG; Srikantan V; Refaeli Y; Prabhu A; Sato A; Williams WV; Weiner DB; Ugen KE
DNA Cell Biol; 2000 Apr; 19(4):243-52. PubMed ID: 10798448
[TBL] [Abstract][Full Text] [Related]
3. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
Losman B; Bolmstedt A; Schønning K; Björndal A ; Westin C; Fenyö EM; Olofsson S
AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1067-76. PubMed ID: 11485624
[TBL] [Abstract][Full Text] [Related]
4. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein.
Shotton C; Arnold C; Sattentau Q; Sodroski J; McKeating JA
J Virol; 1995 Jan; 69(1):222-30. PubMed ID: 7527084
[TBL] [Abstract][Full Text] [Related]
6. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains.
Moore JP; Sattentau QJ; Yoshiyama H; Thali M; Charles M; Sullivan N; Poon SW; Fung MS; Traincard F; Pinkus M
J Virol; 1993 Oct; 67(10):6136-51. PubMed ID: 7690418
[TBL] [Abstract][Full Text] [Related]
7. The monoclonal CD4 antibody M-T413 inhibits cellular infection with human immunodeficiency virus after viral attachment to the cell membrane: an approach to postexposure prophylaxis.
Rieber EP; Federle C; Reiter C; Krauss S; Gürtler L; Eberle J; Deinhardt F; Riethmüller G
Proc Natl Acad Sci U S A; 1992 Nov; 89(22):10792-6. PubMed ID: 1438278
[TBL] [Abstract][Full Text] [Related]
8. A monoclonal antibody to the gp120-CD4 complex has differential effect on HIV-induced syncytium formation and viral infectivity.
Konopka K; Pretzer E; Celada F; Düzgüneş N
J Gen Virol; 1995 Mar; 76 ( Pt 3)():669-79. PubMed ID: 7897355
[TBL] [Abstract][Full Text] [Related]
9. Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies.
Burkly L; Mulrey N; Blumenthal R; Dimitrov DS
J Virol; 1995 Jul; 69(7):4267-73. PubMed ID: 7769687
[TBL] [Abstract][Full Text] [Related]
10. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
McCaffrey RA; Saunders C; Hensel M; Stamatatos L
J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120.
Matsushita S; Matsumi S; Yoshimura K; Morikita T; Murakami T; Takatsuki K
J Virol; 1995 Jun; 69(6):3333-40. PubMed ID: 7538171
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of viral replication by monoclonal antibodies directed against human immunodeficiency virus gp120.
Niedrig M; Harthus HP; Hinkula J; Bröker M; Bickhard H; Pauli G; Gelderblom HR; Wahren B
J Gen Virol; 1992 Sep; 73 ( Pt 9)():2451-5. PubMed ID: 1383412
[TBL] [Abstract][Full Text] [Related]
13. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.
Richardson TM; Stryjewski BL; Broder CC; Hoxie JA; Mascola JR; Earl PL; Doms RW
J Virol; 1996 Feb; 70(2):753-62. PubMed ID: 8551612
[TBL] [Abstract][Full Text] [Related]
14. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.
Trkola A; Purtscher M; Muster T; Ballaun C; Buchacher A; Sullivan N; Srinivasan K; Sodroski J; Moore JP; Katinger H
J Virol; 1996 Feb; 70(2):1100-8. PubMed ID: 8551569
[TBL] [Abstract][Full Text] [Related]
15. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120.
McKeating JA; Shotton C; Cordell J; Graham S; Balfe P; Sullivan N; Charles M; Page M; Bolmstedt A; Olofsson S
J Virol; 1993 Aug; 67(8):4932-44. PubMed ID: 7687306
[TBL] [Abstract][Full Text] [Related]
16. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
[TBL] [Abstract][Full Text] [Related]
17. The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.
Gorny MK; Revesz K; Williams C; Volsky B; Louder MK; Anyangwe CA; Krachmarov C; Kayman SC; Pinter A; Nadas A; Nyambi PN; Mascola JR; Zolla-Pazner S
J Virol; 2004 Mar; 78(5):2394-404. PubMed ID: 14963135
[TBL] [Abstract][Full Text] [Related]
18. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities.
Alsmadi O; Tilley SA
J Virol; 1998 Jan; 72(1):286-93. PubMed ID: 9420226
[TBL] [Abstract][Full Text] [Related]
19. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.
Gorny MK; Williams C; Volsky B; Revesz K; Cohen S; Polonis VR; Honnen WJ; Kayman SC; Krachmarov C; Pinter A; Zolla-Pazner S
J Virol; 2002 Sep; 76(18):9035-45. PubMed ID: 12186887
[TBL] [Abstract][Full Text] [Related]
20. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site.
Vijh-Warrier S; Pinter A; Honnen WJ; Tilley SA
J Virol; 1996 Jul; 70(7):4466-73. PubMed ID: 8676471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
